Text Size

Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Hong Kong Nasopharyngeal Cancer Study Group Limited
Information provided by:
Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:
NCT00563927
First received: November 21, 2007
Last updated: July 6, 2010
Last verified: July 2010
History of Changes

November 21, 2007
July 6, 2010
March 1999
Not Provided
Failure free survival rate [ Time Frame: 5 year ]
Same as current
Complete list of historical versions of study NCT00563927 on ClinicalTrials.gov Archive Site
  • Disease-specific survival rate [ Time Frame: 5-year ]
  • Overall survival rate [ Time Frame: 5-year ]
  • Complication-free rates [ Time Frame: 5-year ]
Same as current
Not Provided
Not Provided
 
Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)
Prospective Randomized Study on Therapeutic Gain Achieved By Addition of Chemotherapy for T1-4N2-3M0 Nasopharyngeal Carcinoma

To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Nasopharyngeal Neoplasms
  • Carcinoma, Squamous Cell
  • Procedure: Conventional RT
  • Drug: Cisplatin
  • Drug: 5-fluorouracil
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
340
October 2009
Not Provided

Inclusion Criteria:

  • Undifferentiated or non-keratinizing carcinoma
  • Tumor staged as N2-3
  • No evidence of distant metastasis M0
  • Performance status:0-2
  • Marrow: WBC >= 4 and platelet >= 100
  • Renal: creatinine clearance >= 60
  • Informed consent

Exclusion Criteria:

  • WHO type I squamous cell carcinoma or adenocarcinoma
  • Age >= 70
  • Palliative intent or tumor extent mandating AP opposing facio-cervical fields
  • Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years
  • Previous radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume
  • Previous chemotherapy
  • Patient is pregnant or lactating
Both
up to 70 Years
Not Provided
Contact information is only displayed when the study is recruiting subjects
China
 
NCT00563927
L/M-77 TO PYH08/79, HARECCTR0500023, NPC99-01
Not Provided
Not Provided
Hospital Authority, Hong Kong
Hong Kong Nasopharyngeal Cancer Study Group Limited
Principal Investigator: Wai Hon LAU, Dr Department of Clinical Oncology, Queen Elizabeth Hospital
Hospital Authority, Hong Kong
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP